This study will evaluate the utilization and dosing of durvalumab and associations with treatment outcomes among patients with unresectable stage III non-small cell lung cancer in an integrated health care system.
This study will evaluate the utilization and dosing of durvalumab and associations with treatment outcomes among patients with unresectable stage III non-small cell lung cancer in an integrated health care system.